

Conquering Disease With Targeted Protein Degradation

Development of AchillesTAG degradation systems and their application to control CAR-T activity

C4 Therapeutics team

490 Arsenal Way, Watertown, MA 02472, USA

BACKGROUND

In recent years, several chemical genetic approaches have emerged that enable the rapid and acute control of target protein homeostasis. These technologies include the auxin-inducible degron (AID)¹, dTAG system², HaloTAG PROTACS^{3,4}, small-molecule-assisted shutoff (SMASh)⁵, cryptic degrons⁶, and the Shield system⁷. These sophisticated technologies have elevated the understanding of target biology in both *in vitro* and *in vivo* settings and exemplified the power of rapid target protein modulation. With these technologies as an inspiration, we aimed to develop additional small molecular degradation tags that would allow for the pharmacologic control of protein homeostasis via heterobifunctional molecule mediated target degradation. We developed two non-overlapping aTAG systems that provide the flexibility in choice of aTAG properties and the opportunity to multiplex aTAG systems within the same context to further explore complex biology. Each aTAG system comes with a suite of degrader molecules with a range of in vivo properties that allow for optionality to meet the needs of a given in vivo application. We applied these aTAG systems as a solution to the increasing demand of mechanisms to control Chimeric Antigen Receptor T cell (CAR-T) activity. We show that pharmacologic control of a chimeric antigen receptor (CAR) via targeted protein degradation (mediated by an aTAG) provides a cellsparing, reversible, and tunable approach.

aTAGs APPLIED TO CAR-T: SMART-CAR



AchillesTAG DEGRADATION SYSTEMS

Engineering novel degradation tags: aTAG









Functional control of SMART-CAR expressing primary T-cells





aTAG1 BASED on MTH1 (NUDT1) Tag size = 17 kDa Physiologic role: Hydrolysis of 8-oxo-dGTP NUDT1^{-/-} mice show no phenotype Acute inhibition or degradation shows no cellular phenotype

-2139 DC₅₀ 1.9 nM, E_{max} 7%

TWO aTAGS + MULTIPLE DEGRADERS Highly potent and rapid acting *In vitro* and *in vivo* applicability

-KIT

Ο

Ο

APPLICATION

0HR

500

- --- DMSO ← ··▲·· CFT-00000766

250

Hours

CFT-00000766 (nM)

REFERENCES

- 1. Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T. & Kanemaki, M. An auxin-based degron system for the rapid depletion of proteins in nonplant cells. Nat Methods 6, 917–922 (2009).
- 2. Nabet, B. et al. The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol 1-11 (2018). doi:10.1038/s41589-018-0021-8
- Buckley, D. L. et al. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. ACS Chemical Biology 10, 1831–1837 (2015).



aTAG2 BASED on BRD9 Tag size = 12.5 kDa Physiologic role: ncBAF complex Conditional dependency in some AML cells





- 4. Neklesa, T. K. et al. Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins. Nature chemical biology 7, 538–43 (2011).
- 5. Chung, H. K. et al. Tunable and reversible drug control of protein production via a self-excising degron. Nat Chem Biol 11, 713–720 (2015).
- 6. Bonger, K. M., Chen, L., Liu, C. W. & Wandless, T. J. Smallmolecule displacement of a cryptic degron causes conditional protein degradation. Nat Chem Biol 7, 531 (2011).
- 7. Banaszynski, L. A., Chen, L.-C. C., Maynard-Smith, L. A., Ooi, A. & Wandless, T. J. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126, 995–1004 (2006).